Position in AKBA
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$62,698
+$8,347 QoQ
Shares Held
54,999
+40.7% QoQ
Ownership
0.020%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#84
of 170 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 29%
Shared 0%
None 71%
Common Shares in AKBA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Arax Advisory Partners holds $14,664,422 across 57 Drug Manufacturers - Specialty & Generic names. AKBA ranks #22 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
24,261 | $4,088,948 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
6,216 | $3,368,015 | |
| 3 | VTRS |
Viatris Inc
|
83,877 | $1,331,966 | |
| 4 | HLN |
Haleon plc
|
81,966 | $764,742 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
21,768 | $737,499 | |
| 6 | ZTS |
Zoetis Inc.
|
9,047 | $650,117 | |
| 7 | TAK |
Takeda Pharmaceutical Co Ltd
|
39,210 | $628,536 | |
| 8 | IRWD |
Ironwood Pharmaceuticals Inc
|
126,966 | $534,526 |
All Filings in AKBA
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $62,698 | 54,999 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $54,351 | 39,102 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $62,939 | 39,093 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $108,108 | 39,600 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $90,333 | 24,817 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $47,648 | 24,817 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $26,030 | 13,700 | Shares | Sole | 2025-02-05 | |
| No filing history on record for this holder in this stock. | ||||||